{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:53:16Z","timestamp":1781653996152,"version":"3.54.5"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-medical ketamine use is becoming increasingly common in the United States (US), but awareness remains limited among US healthcare providers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>Here we present the case of a young woman who developed severe ketamine use disorder in the setting of an acute exacerbation of chronic post-traumatic stress disorder (PTSD). She also demonstrated symptoms concerning for two known complications of chronic ketamine use: gastrointestinal toxicity and ketamine-induced uropathy. Informed by best practices established by specialists in club drug use from the United Kingdom (UK), a multidisciplinary care plan was implemented. The plan included specialist referrals for suspected physical complications and connection with a psychiatrist and psychologist to address underlying mental health conditions driving ketamine use. With individualized, multidisciplinary support, she was able to significantly reduce ketamine use, for a period of time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>US healthcare providers must be aware of non-medical ketamine use and associated harms, including ketamine use disorder, in order to provide effective counseling and treatment to increasing numbers of people using ketamine. In the UK, a multidisciplinary clinic was established to serve people struggling with ketamine and other club drug use, providing a model for effective, patient-centered care that can inform our approach to building systems of care for people who use ketamine and other club drugs in the US.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-026-00645-7","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T02:53:51Z","timestamp":1770173631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Grayken lessons: a multidisciplinary approach to care for a patient with severe ketamine use disorder"],"prefix":"10.1186","volume":"21","author":[{"given":"Maya","family":"Appley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima","family":"Abdulrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Bowden-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"645_CR1","doi-asserted-by":"publisher","DOI":"10.1017\/9781009182126","volume-title":"Textbook of clinical management of Club drugs and Novel Psychoactive substances","author":"D Abdulrahim","year":"2022","unstructured":"Abdulrahim D, Bowden-Jones O. Textbook of clinical management of Club drugs and Novel Psychoactive substances. Cambridge University Press Medicine; 2022."},{"key":"645_CR2","doi-asserted-by":"publisher","first-page":"100454","DOI":"10.1016\/j.abrep.2022.100454","volume":"16","author":"CA Walsh","year":"2022","unstructured":"Walsh CA, Livne O, Shmulewitz D, Stohl M, Hasin DS. Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002-2019. Addictive Behaviors Rep. 2022, December;16:100454. https:\/\/doi.org\/10.1016\/j.abrep.2022.100454.","journal-title":"Addictive Behaviors Rep"},{"issue":"7","key":"645_CR3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1176\/appi.ajp.2017.17020239","volume":"174","author":"ST Wilkinson","year":"2017","unstructured":"Wilkinson ST, Toprak M, Turner MS, Levine SP, Katz RB, Sanacora G. A Survey of the clinical, off-label use of ketamine as a treatment for Psychiatric Disorders. Am J Psychiatry. 2017, July;174(7):695\u201396. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17020239.","journal-title":"Am J Psychiatry"},{"key":"645_CR4","doi-asserted-by":"publisher","first-page":"107889","DOI":"10.1016\/j.drugalcdep.2020.107889","volume":"209","author":"JJ Palamar","year":"2020","unstructured":"Palamar JJ, Keyes KM. Trends in Drug use among electronic dance Music Party Attendees in New York City, 2016-2019. Drug And Alcohol Depend. 2020, April;209:107889. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.107889.","journal-title":"Drug And Alcohol Depend"},{"key":"645_CR5","unstructured":"World Drug Report 2019. U Nations Office On Drugs And Crime. 2019. https:\/\/wdr.unodc.org\/wdr2019\/en\/cannabis-and-hallucinogens.html."},{"key":"645_CR6","unstructured":"Winstock AR, Maier LJ, ZhuParris A, Davies E, Puljevic C, Kuypers KPC, et al. Gobal Drug Survey (GDS) 2021 key findings report. 2021."},{"issue":"11","key":"645_CR7","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.2105\/AJPH.2021.306486","volume":"111","author":"JJ Palamar","year":"2021","unstructured":"Palamar JJ, Rutherford C, Keyes KM. Trends in ketamine use, exposures, and Seizures in the United States up to 2019. Am J Public Health. 2021, November;111(11):2046\u201349. https:\/\/doi.org\/10.2105\/AJPH.2021.306486.","journal-title":"Am J Public Health"},{"issue":"7","key":"645_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1001\/jamapsychiatry.2023.1423","volume":"80","author":"JJ Palamar","year":"2023","unstructured":"Palamar JJ, Wilkinson ST, Carr TH, Rutherford C, Cottler LB. Trends in illicit ketamine Seizures in the US from 2017 to 2022. JAMA Psychiatry. 2023, July, 1;80(7):750. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.1423.","journal-title":"JAMA Psychiatry"},{"key":"645_CR9","doi-asserted-by":"publisher","first-page":"101230","DOI":"10.1016\/j.lana.2025.101230","volume":"51","author":"JJ Palamar","year":"2025","unstructured":"Palamar JJ, Rutherford C, Keyes KM. Trends in nonmedical ketamine use, Poisonings, related deaths, pharmaceutical diversions, and law enforcement Seizures: results from Annual population-based repeated cross-Sectional studies. The Lancet Reg Health - Americas. 2025, November;51:101230. https:\/\/doi.org\/10.1016\/j.lana.2025.101230.","journal-title":"The Lancet Reg Health - Americas"},{"key":"645_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jad.2024.12.108","volume":"373","author":"KH Yang","year":"2025","unstructured":"Yang KH, Kepner W, Cleland CM, Palamar JJ. Trends and Characteristics in ketamine use among US adults with and without depression, 2015-2022. J Affective Disord. 2025, March;373:345\u201352. https:\/\/doi.org\/10.1016\/j.jad.2024.12.108.","journal-title":"J Affective Disord"},{"key":"645_CR11","doi-asserted-by":"publisher","unstructured":"Yockey RA. Past-year ketamine use: evidence from a United States Population, 2015-2019. J Psychoact Drugs. 2022, March, 29;1\u20137. https:\/\/doi.org\/10.1080\/02791072.2022.2058896.","DOI":"10.1080\/02791072.2022.2058896"},{"key":"645_CR12","unstructured":"\u201cMonitoring the Future National Survey Results on Drug Use. 2022. University of Michigan. Institute for Social Research: National Institute on Drug Abuse; n.d. https:\/\/go.exlibris.link\/MSrXYf1X."},{"key":"645_CR13","unstructured":"\u201cNDEWS Special Rapid Street Report: Past 12-Month Ketamine Use in 17 US Cities 2021-2023. Natl Drug Early Warning System (NDEWS). 2023. https:\/\/mcusercontent.com\/599b365ac77a0b62ed5b50279\/files\/c93bbb09-1e7e-05ef-2e26-e43d06fb1d81\/NDEWS_2023_RSR_Ketamine_2023__2_.pdf?ct=t(EMAIL_CAMPAIGN_2_1_2023_11_38_COPY_01)."},{"issue":"1","key":"645_CR14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11606-020-05672-x","volume":"36","author":"JJ Palamar","year":"2021","unstructured":"Palamar JJ, Salomone A, Rutherford C, Keyes KM. Extensive underreported exposure to ketamine among electronic dance Music Party Attendees. J Gener Intern Med. 2021, January;36(1):235\u201337. https:\/\/doi.org\/10.1007\/s11606-020-05672-x.","journal-title":"J Gener Intern Med"},{"key":"645_CR15","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425787","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed., text rev.). 2022. https:\/\/doi.org\/10.1176\/appi.books.9780890425787.","edition":"5th"},{"issue":"6","key":"645_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1192\/pb.bp.113.042713","volume":"37","author":"O Bowden-Jones","year":"2013","unstructured":"Bowden-Jones O. \u2018Legal highs\u2019 and other \u2018Club drugs\u2019: why the song and dance? The Psychiatrist. 2013, June;37(6):185\u201387. https:\/\/doi.org\/10.1192\/pb.bp.113.042713.","journal-title":"The Psychiatrist"},{"key":"645_CR17","unstructured":"Office for National Statistics (ONS), released 14 December ONS Website, Article, Drug Misuse In Engl And W. 2023. year ending March 2023."},{"key":"645_CR18","unstructured":"GOV.UK. Adult substance misuse treatment statistics 2023 to 2024: report. https:\/\/www.gov.uk\/government\/statistics\/substance-misuse-treatment-for-adults-statistics-2023-to-2024\/adult-substance-misuse-treatment-statistics-2023-to-2024-report. Accessed November 30, 2025."},{"key":"645_CR19","unstructured":"\u201cNDTMS - National Drug and Alcohol Treatment Monitoring System. https:\/\/www.ndtms.net\/. Accessed December 1, 2025."},{"key":"645_CR20","unstructured":"\u201cNovel Psychoactive Treatment: UK Network (NEPTUNE). https:\/\/www.cnwl.nhs.uk\/neptune. Accessed March 7, 2024."},{"key":"645_CR21","unstructured":"\u201cAddiction to Medication: Improving Care (ATOMIC). https:\/\/addiction-to-medication.org\/atomic\/. Accessed March 7, 2024."},{"key":"645_CR22","doi-asserted-by":"publisher","unstructured":"Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A Single-Question Screening Test for Drug use in primary care. Archiv Intern Med. 2010;170(13). https:\/\/doi.org\/10.1001\/archinternmed.2010.140.","DOI":"10.1001\/archinternmed.2010.140"},{"issue":"7","key":"645_CR23","doi-asserted-by":"publisher","first-page":"e784.9","DOI":"10.1016\/j.amjmed.2015.02.007","volume":"128","author":"J McNeely","year":"2015","unstructured":"McNeely J, Strauss SM, Saitz R, et al. A Brief patient self-administered substance use Screening tool for primary care: two-site validation study of the substance use Brief Screen (SUBS). The Am J Med. 2015;128(7):.e784.9\u2013784.19. https:\/\/doi.org\/10.1016\/j.amjmed.2015.02.007.","journal-title":"The Am J Med"},{"key":"645_CR24","doi-asserted-by":"publisher","unstructured":"Bradley KA, Lapham GT, Lee AK. Screening for Drug use in primary care: practical Implications of the New USPSTF Recommendation. JAMA Intern Med. 2020). 1050;180(8). https:\/\/doi.org\/10.1001\/jamainternmed.2019.7335.","DOI":"10.1001\/jamainternmed.2019.7335"},{"issue":"22","key":"645_CR25","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1001\/jama.2020.8020","volume":"323","author":"AH Krist","year":"2020","unstructured":"Krist AH, Mangione CM, Barry MJ, et al. Screening for Unhealthy Drug use: US Preventive services Task Force Recommendation Statement. JAMA. 2020;323(22):2301. https:\/\/doi.org\/10.1001\/jama.2020.8020.","journal-title":"JAMA"},{"issue":"22","key":"645_CR26","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1001\/jama.2019.21381","volume":"323","author":"CD Patnode","year":"2020","unstructured":"Patnode CD, Perdue LA, Rushkin M, et al. Screening for Unhealthy Drug use: updated evidence report and Systematic Review for the US Preventive services Task Force. JAMA. 2020;323(22):2310\u201328. https:\/\/doi.org\/10.1001\/jama.2019.21381.","journal-title":"JAMA"},{"issue":"22","key":"645_CR27","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1001\/jama.2019.20152","volume":"323","author":"R Saitz","year":"2020","unstructured":"Saitz R. Screening for Unhealthy Drug use: neither an unreasonable Idea nor an evidence-based practice. JAMA. 2020;323(22):2263\u201365. https:\/\/doi.org\/10.1001\/jama.2019.20152.","journal-title":"JAMA"},{"key":"645_CR28","unstructured":"\u201cTAPS Tobacco, Alcohol, Prescription Medication, and Other Substance Use Tool. 2017 September. https:\/\/nida.nih.gov\/taps2\/."},{"key":"645_CR29","unstructured":"\u201cNIDA Modified ASSIST. National institute on Drug abuse. 2011 December. https:\/\/nida.nih.gov\/sites\/default\/files\/pdf\/screening_qr.pdf."},{"key":"645_CR30","doi-asserted-by":"publisher","unstructured":"Fitzgerald, et al. Test-retest reliability and cross-cultural applicability of DSM-5 adopted Diagnostic criteria for ketamine use Disorders. Drug And Alcohol Depend. 2021, November;228. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.109056.","DOI":"10.1016\/j.drugalcdep.2021.109056"},{"key":"645_CR31","unstructured":"Honest Information about Drugs | FRANK. https:\/\/talktofrank.com\/. Accessed 23 Dec. 2025."},{"key":"645_CR32","unstructured":"\u201cResource: Harm Reduction & Overdose Prevention: Ketamine. San Francisco AIDS foundation. https:\/\/www.sfaf.org\/resource-library\/harm-reduction-overdose-prevention-ketamine\/. Accessed 23 Dec. 2025."},{"key":"645_CR33","unstructured":"Winstock AR, Munksgaard R, Davies E, Ferris J, ZhuParris A, Barratt M. Global Drug Survey 2022 Drug Trend Report: Time, Music, Clubbing, Age, and Diet. 2022."},{"key":"645_CR34","doi-asserted-by":"publisher","unstructured":"Palamar JJ, Le A. Media coverage about medical benefits of MDMA and Ketamine affects Perceived likelihood of engaging in non-medical use. Addict Res Theory 30, no. 2(March 4, 2022b):96\u2013103. https:\/\/doi.org\/10.1080\/16066359.2021.1940972.","DOI":"10.1080\/16066359.2021.1940972"},{"key":"645_CR35","doi-asserted-by":"publisher","unstructured":"Walsh Z, Mollaahmetoglu OM, Rootman J, Golsof S, Keeler J, Marsh B, et al. Ketamine for the treatment of mental health and substance use Disorders: Comprehensive Systematic Review. BJPsych Open. 2022, January;8(1). https:\/\/doi.org\/10.1192\/bjo.2021.1061.","DOI":"10.1192\/bjo.2021.1061"},{"key":"645_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/JPR.S403323","volume":"16","author":"E Peskin","year":"2023","unstructured":"Peskin E, Gudin J, Schatman ME. Increased demand for ketamine infusions and associated complexities. J Pain Res. 2023, January;16:295\u201399. https:\/\/doi.org\/10.2147\/JPR.S403323.","journal-title":"J Pain Res"},{"key":"645_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.drugalcdep.2016.10.004","volume":"169","author":"SS Martins","year":"2016","unstructured":"Martins SS, Mauro CM, Santaella-Tenorio J, Kim JH, Cerda M, Keyes KM, et al. State-level medical Marijuana Laws, Marijuana use and Perceived availability of Marijuana among the general U.S. Population. Drug and Alcohol Depend. 2016, December;169:26\u201332. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.10.004.","journal-title":"Drug and Alcohol Depend"},{"issue":"1","key":"645_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12889-020-8253-4","volume":"20","author":"B Yu","year":"2020","unstructured":"Yu B, Chen X, Chen X, Yan H. Marijuana legalization and historical Trends in Marijuana use among US residents aged 12-25. Results from the 1979\u20132016 National Survey on Drug use and health. BMC Public Health. 2020, December;20(1):156. https:\/\/doi.org\/10.1186\/s12889-020-8253-4.","journal-title":"BMC Public Health"},{"issue":"6","key":"645_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1001\/jamapsychiatry.2017.0724","volume":"74","author":"DS Hasin","year":"2017","unstructured":"Hasin DS, Sarvet AL, Cerd\u00e1 M, Keyes KM, Stohl M, Galea S, et al. US adult illicit cannabis use, cannabis use disorder, and medical Marijuana Laws. JAMA Psychiatry. 2017, June;74(6):579\u2013610. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.0724.","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"645_CR40","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S2215-0366(16)30208-5","volume":"3","author":"WM Compton","year":"2016","unstructured":"Compton WM, Han B, Jones CM, Blanco C, Hughes A. Marijuana use and use Disorders in adults in the USA, 2002-14. Analysis of Annual cross-Sectional surveys. The Lancet Psychiatry. 2016, October, 1;3(10):954\u201364. https:\/\/doi.org\/10.1016\/S2215-0366(16)30208-5.","journal-title":"The Lancet Psychiatry"},{"key":"645_CR41","doi-asserted-by":"publisher","DOI":"10.12809\/hkmj177086","author":"Y Hong","year":"2018","unstructured":"Hong Y, Yee C, Tam Y, Wong JH, Lai P, Ng C. Management of complications of ketamine Abuse: 10 years\u2019 experience in Hong Kong. Hong Kong Med J. 2018, April, 6. https:\/\/doi.org\/10.12809\/hkmj177086.","journal-title":"Hong Kong Med J"},{"issue":"1","key":"645_CR42","first-page":"6","volume":"16","author":"SH Ng","year":"2010","unstructured":"Ng SH, Tse ML, Ng HW, Lau FL. Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. Hong Kong Med J = Xianggang yi xue za zhi. 2010;16(1):6\u201311.","journal-title":"Hong Kong Med J = Xianggang yi xue za zhi"},{"issue":"6","key":"645_CR43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/15563650.2023.2212125","volume":"61","author":"LJ Schep","year":"2023","unstructured":"Schep LJ, Slaughter RJ, Watts M, Mackenzie E, Gee P. The clinical toxicology of ketamine. Clin Toxicol (philadelphia, Pa.). 2023;61(6):415\u201328. https:\/\/doi.org\/10.1080\/15563650.2023.2212125.","journal-title":"Clin Toxicol (philadelphia, Pa.)"},{"issue":"4","key":"645_CR44","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0736-4679(00)00162-1","volume":"18","author":"AL Weiner","year":"2000","unstructured":"Weiner AL, Vieira L, McKay CA, Bayer MJ. Ketamine abusers presenting to the Emergency department: a case series. The J Emerg Med. 2000;18(4):447\u201351. https:\/\/doi.org\/10.1016\/S0736-4679(00)00162-1.","journal-title":"The J Emerg Med"},{"key":"645_CR45","doi-asserted-by":"publisher","first-page":"e0207927","DOI":"10.1371\/journal.pone.0207927","volume-title":"PLOS ONE","author":"SS-D Yang","year":"2018","unstructured":"Yang SS-D, Jang M-Y, Lee K-H, Hsu W-T, Chen Y-C, Chen W-S, et al. Sexual and bladder dysfunction in male ketamine abusers: a large-scale Questionnaire study. In: Fischer GABRIELE, editor. PLOS ONE. Vol. 13, no. 11 (2018 November 28. p. e0207927. https:\/\/doi.org\/10.1371\/journal.pone.0207927."},{"key":"645_CR46","doi-asserted-by":"publisher","unstructured":"Palamar JJ, Fitzgerald ND, Grundy DJ, Black JC, Jewell JS, Cottler LB. Characteristics of Poisonings involving ketamine in the United States, 2019-2021. J Psychopharmacol. 2022. https:\/\/doi.org\/10.1177\/02698811221140006.","DOI":"10.1177\/02698811221140006"},{"key":"645_CR47","doi-asserted-by":"publisher","unstructured":"Palamar JJ, Le A. Prevalence of self-reported adverse effects associated with Drug use among nightclub and festival Attendees, 2019-2022. Drug And Alcohol Depend Rep. 7(June 2023a):100149. https:\/\/doi.org\/10.1016\/j.dadr.2023.100149.","DOI":"10.1016\/j.dadr.2023.100149"},{"issue":"8","key":"645_CR48","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1097\/PEC.0000000000000502","volume":"33","author":"JW Wang","year":"2017","unstructured":"Wang JW, Kivovich V, Gordon L. Ketamine Abuse Syndrome: hepatobiliary and urinary Pathology among adolescents in Flushing, NY. Pediatr Emerg Care. 2017, August;33(8):e24\u201326. https:\/\/doi.org\/10.1097\/PEC.0000000000000502.","journal-title":"Pediatr Emerg Care"},{"issue":"2","key":"645_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugpo.2004.12.003","volume":"16","author":"J Copeland","year":"2005","unstructured":"Copeland J, Dillon P. The health and psycho-social consequences of ketamine use. The Int J Drug Policy. 2005;16(2):122\u201331. https:\/\/doi.org\/10.1016\/j.drugpo.2004.12.003.","journal-title":"The Int J Drug Policy"},{"key":"645_CR50","doi-asserted-by":"publisher","first-page":"7107","DOI":"10.3402\/ehtj.v4i0.7107","volume":"4","author":"SS Kalsi","year":"2011","unstructured":"Kalsi SS, Wood DM, Dargan PI. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerging Health Threats J. 2011;4:7107. https:\/\/doi.org\/10.3402\/ehtj.v4i0.7107.","journal-title":"Emerging Health Threats J"},{"issue":"1","key":"645_CR51","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1360-0443.2011.03576.x","volume":"107","author":"CJA Morgan","year":"2012","unstructured":"Morgan CJA, Curran HV. Ketamine use: a Review. Addict (abingdon, Engl). 2012;107(1):27\u201338. https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03576.x.","journal-title":"Addict (abingdon, Engl)"},{"issue":"3","key":"645_CR52","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.drugalcdep.2008.01.024","volume":"95","author":"L Muetzelfeldt","year":"2008","unstructured":"Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJA, Curran HV. Journey through the K-Hole: phenomenological aspects of ketamine use. Drug And Alcohol Depend. 2008, June;95(3):219\u201329. https:\/\/doi.org\/10.1016\/j.drugalcdep.2008.01.024.","journal-title":"Drug And Alcohol Depend"},{"issue":"1","key":"645_CR53","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.drugpo.2014.07.004","volume":"26","author":"H Uosukainen","year":"2015","unstructured":"Uosukainen H, Tacke U, Winstock AR. Self-reported prevalence of Dependence of MDMA compared to cocaine, Mephedrone and ketamine among a sample of non-medical poly-Drug users. Int J Drug Policy. 2015, January;26(1):78\u201383. https:\/\/doi.org\/10.1016\/j.drugpo.2014.07.004.","journal-title":"Int J Drug Policy"},{"issue":"11","key":"645_CR54","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/j.1464-410X.2008.07920.x","volume":"102","author":"PS-K Chu","year":"2008","unstructured":"Chu PS-K, Ma W-K, Wong SC-W, Chu RW-H, Cheng C-H, Wong S, et al. The destruction of the lower urinary tract by ketamine Abuse: a New Syndrome? BJU Int. 2008, December;102(11):1616\u201322. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.07920.x.","journal-title":"BJU Int"},{"issue":"4","key":"645_CR55","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1569-9056(09)60202-5","volume":"8","author":"A Cottrell","year":"2009","unstructured":"Cottrell A, Warren K, Ayres R, Weinstock P, Gillatt DA. The relationship of chronic non-medical ketamine use and severe bladder Pathology: presentation, management of symptoms and Public health concerns. Eur Urology. 2009;8(4):170.","journal-title":"Eur Urology"},{"key":"645_CR56","doi-asserted-by":"publisher","unstructured":"Anderson DJ, Zhou J, Cao D, McDonald M, Guenther M, Hasoon J, et al. Ketamine-induced cystitis: a Comprehensive Review of the urologic effects of this Psychoactive Drug. Health Phychol Res. 2022, September, 15;10(3). https:\/\/doi.org\/10.52965\/001c.38247.","DOI":"10.52965\/001c.38247"},{"issue":"4","key":"645_CR57","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/nau.24341","volume":"39","author":"D Castellani","year":"2020","unstructured":"Castellani D, Pirola GM, Gubbiotti M, Rubilotta E, Gudaru K, Gregori A, et al. What urologists need to know about ketamine-induced uropathy: a Systematic Review. Neurourol And Urodynamics. 2020;39(4):1049\u201362. https:\/\/doi.org\/10.1002\/nau.24341.","journal-title":"Neurourol And Urodynamics"},{"key":"645_CR58","doi-asserted-by":"publisher","unstructured":"Belal M, Downey A, Doherty R, Ali A, Hashim H, Kozan A, et al. British Association of urological Surgeons Consensus statements on the management of ketamine uropathy. BJU Int 134, no. 2(August 2024):148\u201354. https:\/\/doi.org\/10.1111\/bju.16404.","DOI":"10.1111\/bju.16404"},{"issue":"12","key":"645_CR59","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/j.1464-410X.2010.10031","volume":"107","author":"D Wood","year":"2011","unstructured":"Wood DI, Cottrell A, Baker SC, Southgate J, Harris M, Fulford S, et al. Recreational ketamine: from pleasure to pain. BJU Int. 2011;107(12):1881\u201384. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.10031.","journal-title":"BJU Int"},{"issue":"5","key":"645_CR60","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/ADM.0000000000001340","volume":"18","author":"E Roberts","year":"2024","unstructured":"Roberts E, Sanderson E, Guerrini I. The pharmacological management of ketamine use disorder: a Systematic Review. J Addict Med. 2024, October;18(5):574. https:\/\/doi.org\/10.1097\/ADM.0000000000001340.","journal-title":"J Addict Med"},{"issue":"4","key":"645_CR61","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3109\/14659891.2015.1040092","volume":"21","author":"R Bhad","year":"2016","unstructured":"Bhad R, Dayal P, Kumar S, Ambekar A. The Drug ketamine: a Double edged sword for mental health professionals. J Subst Use. 2016;21(4):341\u201343. https:\/\/doi.org\/10.3109\/14659891.2015.1040092.","journal-title":"J Subst Use"},{"issue":"8","key":"645_CR62","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.addbeh.2014.04.004","volume":"39","author":"A Garg","year":"2014","unstructured":"Garg A, Sinha P, Kumar P, Prakash O. Use of Naltrexone in ketamine Dependence. Addictive Behaviors. 2014;39(8):1215\u201316. https:\/\/doi.org\/10.1016\/j.addbeh.2014.04.004.","journal-title":"Addictive Behaviors"},{"key":"645_CR63","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.mehy.2015.11.011","volume":"87","author":"M-C Huang","year":"2016","unstructured":"Huang M-C, Chen L-Y, Chen C-K, Lin S-K. Potential benefit of Lamotrigine in managing ketamine use disorder. Med Hypotheses. 2016, February;87:97\u2013100. https:\/\/doi.org\/10.1016\/j.mehy.2015.11.011.","journal-title":"Med Hypotheses"},{"issue":"S1","key":"645_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0924-9338(15)30856-7","volume":"30","author":"LP G\u00f3mez","year":"2015","unstructured":"G\u00f3mez LP, Mart\u00ednez MG, Fern\u00e1ndez AG, et al. Possible Use of Paliperidone Palmitate in Ketamine Addiction. Eur Psychiatry. 2015;30(S1):1\u20131. https:\/\/doi.org\/10.1016\/S0924-9338(15)30856-7.","journal-title":"Eur Psychiatry"},{"issue":"6","key":"645_CR65","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/00045391-200007060-00008","volume":"7","author":"AJ Giannini","year":"2000","unstructured":"Giannini AJ, Underwood NA, Condon M. Acute ketamine intoxication treated by haloperidol: a preliminary study. Am J Ther. 2000;7(6):389\u201391. https:\/\/doi.org\/10.1097\/00045391-200007060-00008.","journal-title":"Am J Ther"},{"issue":"5","key":"645_CR66","first-page":"593","volume":"43","author":"M B\u0142achut","year":"2009","unstructured":"B\u0142achut M, So\u0142owi\u00f3w K, Janus A, et al. A case of ketamine dependence. Psychiatria Polska. 2009;43(5):593\u201399.","journal-title":"Psychiatria Polska"},{"issue":"1","key":"645_CR67","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/ajad.12978","volume":"29","author":"L-Y Chen","year":"2020","unstructured":"Chen L-Y, Chen C-K, Chen C-H, Chang H-M, Huang M-C, Xu K. Association of craving and depressive symptoms in ketamine-dependent patients undergoing withdrawal treatment. The Am J On Addictions. 2020;29(1):43\u201350. https:\/\/doi.org\/10.1111\/ajad.12978.","journal-title":"The Am J On Addictions"},{"issue":"8","key":"645_CR68","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/j.1360-0443.2006.01494.x","volume":"101","author":"DG Critchlow","year":"2006","unstructured":"Critchlow DG. A case of ketamine Dependence with discontinuation symptoms. Addict (abingdon, Engl). 2006;101(8):1212\u201313. https:\/\/doi.org\/10.1111\/j.1360-0443.2006.01494.x.","journal-title":"Addict (abingdon, Engl)"},{"issue":"1","key":"645_CR69","first-page":"31","volume":"44","author":"DK Lim","year":"2003","unstructured":"Lim DK. Ketamine associated psychedelic effects and Dependence. Singapore Med J. 2003;44(1):31\u201334.","journal-title":"Singapore Med J"},{"issue":"3","key":"645_CR70","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/0310057X0203000323","volume":"30","author":"HR Pal","year":"2002","unstructured":"Pal HR, Berry N, Kumar R, Ray R. Ketamine Dependence. Anaesth And Intensive Care. 2002;30(3):382\u201384. https:\/\/doi.org\/10.1177\/0310057X0203000323.","journal-title":"Anaesth And Intensive Care"},{"issue":"7","key":"645_CR71","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1176\/appi.ajp.2020.20101480","volume":"178","author":"N Roxas","year":"2021","unstructured":"Roxas N, Ahuja C, Isom J, Wilkinson ST, Capurso N. A potential case of acute ketamine withdrawal: clinical Implications for the treatment of refractory depression. The Am J Psychiatry. 2021;178(7):588\u201391. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20101480.","journal-title":"The Am J Psychiatry"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00645-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00645-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00645-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:03:48Z","timestamp":1781651028000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-026-00645-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["645"],"URL":"https:\/\/doi.org\/10.1186\/s13722-026-00645-7","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"30 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient provided verbal consent for publication of this case report. All potentially identifying information has been removed to protect patient privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.R.G. is Associate Program Director of the Addiction Medicine Fellowship at MGH and president-elect of the Massachusetts Society of Addiction Medicine (MASAM). She is a paid clinical consultant for the Massachusetts Consultation Service for Treatment of Addiction and Pain (MCSTAP) and for acute treatment services (Gavin Foundation and Baycove). At the time of the manuscript submission, she was Medical Director of the MGH HOPE Clinic. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}